India approves Oxford's, Bharat Biotech's COVID-19 vaccines for restricted emergency use

Indias drugs regulator on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation driveThe approval by the Drugs Controller General of India DCGI was given on the basis of recommendations submitted by a COVID-19 subject expert committee SEC of the Central Drugs Standard Control Organisation CDSCO.

PTI | New Delhi | Updated: 03-01-2021 11:47 IST | Created: 03-01-2021 11:47 IST
India approves Oxford's, Bharat Biotech's COVID-19 vaccines for restricted emergency use

India's drugs regulator on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive

The approval by the Drugs Controller General of India (DCGI) was given on the basis of recommendations submitted by a COVID-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). “After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation,'' DCGI Dr V G Somani told a press conference here

This paves the way for the roll out of at least two vaccines in India in the coming days. The Serum Institute of India, the world's largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield. Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). Serum Institute of India’s CEO Adar Poonawalla tweeted, “Happy new year, everyone! All the risks Serum Institute of India took with stockpiling the vaccine, have finally paid off. COVISHIELD, India's first COVID-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks.” Also, the authority granted Cadila Healthcare the permission to conduct the Phase III clinical trial of its vaccine candidate in India, Somani said.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Why unequal access to coronavirus vaccines is a threat to us all

... ...

India’s love affair with fossil fuels: the path to sustainable development?

... ...

Videos

Latest News

Chief: Capitol Police were warned of violence before riot

Capitol Police knew armed extremists were primed for violence at the iconic building on January 6 and even provided officers with assault rifles to protect lawmakers, the acting chief acknowledged Wednesday. But the wild invasion of the Cap...

ICC signs deal with IMG, to live stream 541 games across 3 World Cups

A total of 541 matches across three upcoming World Cups will be broadcast globally following a live streaming deal between the International Cricket Council and IMG, the games governing body announced on Thursday.The live streaming deal, wh...

Andhra CM urges Piyush Goyal to give railway lands to poor families, offers alternative land

Urging Union Railways Minister Piyush Goyal to give the Indian Railways-owned land to nearly 800 poor families situated there, Andhra Pradesh Chief Minister YS Jaganmohan Reddy on Wednesday offered alternative land to the Railways in lieu o...

India, Pakistan agree to follow all ceasefire pacts

India and Pakistan have agreed to strictly observe all agreements on a ceasefire along the Line of Control LoC and other sectors, according to a joint statement on Thursday.The decision on a ceasefire, effective since Wednesday midnight, wa...

Give Feedback